Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000950170-25-097088
Filing Date
2025-07-21
Accepted
2025-07-21 09:00:04
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 11476
  Complete submission text file 0000950170-25-097088.txt   13263
Mailing Address 3580 CARMEL MOUNTAIN ROAD, SUITE 200 SAN DIEGO CA 92130
Business Address 3580 CARMEL MOUNTAIN ROAD, SUITE 200 SAN DIEGO CA 92130 858-727-1040
Connect Biopharma Holdings Ltd (Subject) CIK: 0001835268 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-92416 | Film No.: 251135887
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O MAPLES CORPORATE SERVICES LIMITED BOX 309, UGLAND HOUSE GRAND CAYMAN E9 KY1-1104
Business Address C/O MAPLES CORPORATE SERVICES LIMITED BOX 309, UGLAND HOUSE GRAND CAYMAN E9 KY1-1104 86 21 60252100
Panacea Innovation Ltd (Filed by) CIK: 0002010692 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13D/A